Recent studies revealed CD47’s co-expression with IFT57 and its impact on cancer prognosis, suggesting dual targeting of CD47 and IFT57 may enhance efficacy and reduce CD47-targeted therapy’s side effects [35]. Here, IFT57 is linked to cancer.